Irbesartan/Hct Stada

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hct Stada, is an angiotensin II receptor blocker / thiazide diuretic presented as an unspecified‑strength tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure and is often used in combination regimens to enhance cardiovascular risk reduction.

GNH USA supplies Irbesartan/Hct Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory adherence. The company adheres to stringent Good Distribution Practice standards and provides comprehensive support for regulatory documentation, customs clearance and temperature‑controlled logistics where required.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to control elevated blood pressure.

Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension. Secondary hypertension: assists in blood pressure control when hypertension is due to identifiable causes. Hypertension with fluid retention: combines vasodilation and diuresis to manage blood pressure and excess fluid. High cardiovascular risk patients: contributes to overall risk reduction when added to standard therapy.

Irbesartan/Hydrochlorothiazide may be associated with a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Dizziness: light‑headed sensation, especially after the first dose. - Headache: mild to moderate head pain. - Fatigue: feeling of tiredness or reduced energy. - Increased urination: due to the diuretic effect.

Serious or Rare Side Effects: - Hyperkalemia: elevated potassium levels that may cause cardiac arrhythmia. - Acute kidney injury: sudden decline in renal function, indicated by rising creatinine. - Severe allergic reaction: rash, swelling, or difficulty breathing (anaphylaxis).

Before prescribing Irbesartan/Hydrochlorothiazide, clinicians should evaluate several safety considerations.

Renal function: assess baseline kidney function and monitor serum creatinine. Electrolytes: check potassium and sodium levels, especially in patients on other diuretics. Pregnancy: avoid use during pregnancy due to potential fetal toxicity. Concomitant drugs: review use of potassium‑sparing agents or NSAIDs that may affect renal handling. Elderly patients: start with lower doses and monitor for orthostatic hypotension. Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - ACE inhibitors or other ARBs: combined use may increase risk of hyperkalemia and renal impairment. - Lithium: concomitant use can raise lithium levels, leading to toxicity. - NSAIDs: may reduce antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely): - Potassium‑sparing diuretics: may cause additive hyperkalemia. - Antidiabetic drugs: thiazide component can increase blood glucose, requiring dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan concentrations.